Lupin Launches Prucalopride Tablets In US Market

Lupin Ltd. on Thursday announced the launch of prucalopride tablets in 1 milligram and 2 milligram strengths in the US, following approval from the US Food and Drug Administration a day earlier.

Prucalopride is a bioequivalent of Motegrity tablets, developed by Takeda Pharmaceuticals USA Inc., and is prescribed for the treatment of chronic idiopathic constipation in adults. The product recorded estimated sales of $184 million in the 12 months to April, according to market research firm IQVIA, Lupin said in a release.